The last scientific round table of the IX International Symposium on Lipodystrophies, entitled "Natural History and Update of Lipodystrophies", started at 4:30 pm on Friday 22 October and was moderated by Dr. Rebecca Brown (MD, MSHc, Lasker Tenure Track Investigator, NIDDK, NIH, Bethesda, USA) and member of the AELIP expert committee.
The first of the presentations took us directly to Michigan (USA) and dealt with the differential diagnosis of partial lipodystrophies.
After Dr. Oral's brilliant intervention, the symposium returned to Spain to listen to the presentation entitled: Progerias: Is a paradigm shift necessary? The speaker was Dr. David Araújo-Vilar, member of the AELIP expert committee and Professor of Medicine at the Faculty of Medicine of the University of Santiago de Compostela, Spain.
The symposium then moved on to Latin America and more specifically to Argentina where Dr. Carla Musso, Endocrinologist, Favaloro Foundation, Buenos Aires, Argentina and member of the AELIP advisory committee gave her presentation "Lipodystrophies: impact of appropriate treatment".
The symposium then moved to the USA to hear the presentation "Metreleptin improves left ventricular hypertrophy in patients with generalised lipodystrophy" given by the moderator of the panel, Dr Rebecca Brown, MD, MSHc, Lasker Tenure Track Investigator, NIDDK, NIH, Bethesda, USA.
To conclude the round table, the event moved to France with Dr Helena Mosbah, MD, Endocrinologist, National Reference Centre for Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Saint-Antoine Hospital (Paris) who gave a presentation entitled "Therapeutic indications and metabolic effects of metreleptin in patients with Lipodystrophy: real experience of the French reference network in lipodystrophy".
